CA3018145C - TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER - Google Patents

TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER

Info

Publication number
CA3018145C
CA3018145C CA3018145A CA3018145A CA3018145C CA 3018145 C CA3018145 C CA 3018145C CA 3018145 A CA3018145 A CA 3018145A CA 3018145 A CA3018145 A CA 3018145A CA 3018145 C CA3018145 C CA 3018145C
Authority
CA
Canada
Prior art keywords
taurolidine
patient
compounds
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018145A
Other languages
English (en)
French (fr)
Other versions
CA3018145A1 (en
Inventor
H. Paul Redmond
Rolf W. Pfirrmann
Original Assignee
Geistlich Pharma AG
Persevere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG, Persevere Therapeutics Inc filed Critical Geistlich Pharma AG
Publication of CA3018145A1 publication Critical patent/CA3018145A1/en
Application granted granted Critical
Publication of CA3018145C publication Critical patent/CA3018145C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3018145A 2016-03-18 2017-03-17 TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER Active CA3018145C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310275P 2016-03-18 2016-03-18
US62/310,275 2016-03-18
PCT/IB2017/051570 WO2017158570A1 (en) 2016-03-18 2017-03-17 Method of treating triple negative breast cancer

Publications (2)

Publication Number Publication Date
CA3018145A1 CA3018145A1 (en) 2017-09-21
CA3018145C true CA3018145C (en) 2024-09-17

Family

ID=58410400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3018145A Active CA3018145C (en) 2016-03-18 2017-03-17 TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER

Country Status (6)

Country Link
US (1) US10736902B2 (enExample)
EP (1) EP3429614B1 (enExample)
JP (1) JP6933659B2 (enExample)
CA (1) CA3018145C (enExample)
ES (1) ES2945712T3 (enExample)
WO (1) WO2017158570A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CN114096255B (zh) * 2019-05-22 2024-09-10 盖斯特里希医药公司 用于治疗、预防、抑制或减少细胞因子释放的噁噻嗪二氧化物
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
US20220218634A1 (en) * 2021-01-13 2022-07-14 Chengde SHANG Method for inducing mass apoptosis of cancer cells by enhancing the overall acidity in the tumor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20030092707A1 (en) 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US9241943B2 (en) * 2012-06-18 2016-01-26 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
WO2015092614A1 (en) * 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer

Also Published As

Publication number Publication date
EP3429614B1 (en) 2023-05-03
CA3018145A1 (en) 2017-09-21
JP6933659B2 (ja) 2021-09-08
WO2017158570A1 (en) 2017-09-21
ES2945712T3 (es) 2023-07-06
JP2019508476A (ja) 2019-03-28
US20190091233A1 (en) 2019-03-28
US10736902B2 (en) 2020-08-11
EP3429614A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
US10736902B2 (en) Method of treating triple negative breast cancer
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
CN111558044A (zh) 一种包含舒尼替尼的药物组合物及其制剂和应用
KR20230113594A (ko) Pik3ca 돌연변이 암을 치료하기 위한 병용 요법
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
WO2021140478A1 (en) Combination therapy for treating cancer
EP4197539A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
US20150320696A1 (en) Combination therapy for cancer
AU2007325797B2 (en) Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CA3170021A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
WO2020228656A1 (zh) 用于联合治疗软组织肉瘤的喹啉衍生物
BR112021008606A2 (pt) uso de tivozanibe para tratar indivíduos com câncer refratário
KR102363043B1 (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2021114089A1 (en) Methods of using crocetin in treating solid tumors
WO2022171064A1 (zh) 烟酰胺及含有其的组合物的制药用途
KR20250088372A (ko) Btk 분해제와 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合
HK40085748A (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
HK1227400A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211008

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20240913

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20240917

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260414

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729